Human Growth Hormone vs Follistatin-344.

Human growth hormone (hGH, also called somatotropin) is a 191-amino-acid, single-chain polypeptide hormone secreted by somatotroph cells of the anterior pituitary gland. The pharmaceutical form used in medicine and research is recombinant human growth hormone (rhGH, generic name somatropin), an identical 22 kDa sequence manufactured in E. coli or mammalian cells. It is one of the most studied protein hormones, marketed under brands such as Genotropin, Norditropin, Humatrope, Saizen, Nutropin, and Omnitrope.

Follistatin-344 (FS-344) is an alternatively spliced isoform of human follistatin, a naturally occurring secreted glycoprotein that acts as a high-affinity antagonist of several TGF-beta superfamily ligands. The "344" refers to a 344-amino-acid precursor variant; relative to the longer FS-315 serum isoform, it lacks the C-terminal acidic tail and was selected for therapeutic use partly to reduce off-target heparin/cell-surface binding. In gene-therapy programs it is the FS344 transgene that is delivered, not an injected peptide product, although it is now marketed in gray-market channels as a "research peptide."

GH binds a single GH receptor (GHR) that dimerizes and signals through the JAK2/STAT5 pathway, driving transcription of target genes including IGF-1. Much of GH's anabolic and growth-promoting action is mediated indirectly by hepatic and local insulin-like growth factor 1 (IGF-1), while GH itself exerts direct effects that are often metabolically opposite to insulin: it stimulates lipolysis, promotes protein accretion, and induces a state of insulin resistance that raises blood glucose. Endogenous secretion is pulsatile, stimulated by hypothalamic GHRH and ghrelin and suppressed by somatostatin, with negative feedback from IGF-1 and GH itself. The net physiologic effects include longitudinal bone growth at open epiphyses, increased lean body mass, reduced fat mass, and altered glucose and lipid handling.

Follistatin works by binding and neutralizing myostatin (GDF-8) and related ligands such as activin A, GDF-11, and several BMPs, preventing them from engaging activin type II receptors. Because myostatin is a dominant negative regulator of skeletal muscle mass, removing this brake promotes satellite-cell activation, myofiber hypertrophy, and reduced fibrosis. Critically, follistatin neutralizes a broader set of ligands than myostatin-only blockade, which is why follistatin overexpression produces larger muscle gains in animals than myostatin knockout alone. The foundational biology traces to McPherron, Lawler and Lee (Nature, 1997), who showed myostatin loss roughly doubles muscle mass in mice.

The strongest human evidence is for replacement in diagnosed GH deficiency: recombinant somatropin is FDA-approved and supported by randomized trials and systematic reviews (e.g., Health Technology Assessment 2010, PMID 20849734, for pediatric growth disorders) showing improved growth velocity and adult height in children and improved body composition and quality of life in adult GHD (reviewed in Pituitary 2006, PMID 17077947). More recently, a long-acting analog, once-weekly somapacitan, was effective and well tolerated versus placebo and daily GH in adult GHD in a randomized phase 3 trial (J Clin Endocrinol Metab 2020, PMID 32022863). By contrast, evidence for GH in healthy older adults is weak and unfavorable: the landmark Rudman study (N Engl J Med 1990, PMID 2355952) reported body-composition changes in men over 60 but was small and uncontrolled for clinical endpoints, and a systematic review (Liu et al., Ann Intern Med 2007, PMID 17227934) concluded GH produces only small body-composition changes in the healthy elderly while increasing adverse events, and cannot be recommended as anti-aging therapy. Claims of fat loss, muscle gain, or longevity in healthy or athletic populations are not supported by robust controlled human outcome data.

Human evidence is limited to two small, open-label AAV1-delivered FS344 gene-therapy trials from Nationwide Children's Hospital (Mendell and colleagues), not to any injected-peptide product. A Phase 1/2a trial in Becker muscular dystrophy (6 subjects; Mol Ther 2015, PMID 25322757) reported six-minute-walk gains in some treated patients (e.g., +58 m and +125 m in two subjects) with histological evidence of reduced fibrosis and fiber hypertrophy. A companion sporadic inclusion body myositis trial (6 subjects; Mol Ther 2017, PMID 28279643) reported improved annualized six-minute-walk distance versus untreated controls, though responses were heterogeneous and the comparison used a non-randomized matched control group. These are early-phase, unblinded, very small studies; large-animal support comes from a nonhuman-primate follistatin gene-delivery study (Kota et al., Sci Transl Med 2009, PMID 20368179). No randomized controlled trial, and no trial of FS-344 as a standalone injectable peptide, has demonstrated efficacy. The sIBM functional claims also drew a published methodological critique in Molecular Therapy.

Documented adverse effects, drawn largely from the healthy-elderly trials and GHD populations, include fluid retention and edema, arthralgias and joint swelling, carpal tunnel syndrome, and impaired glucose tolerance or new-onset diabetes due to GH-induced insulin resistance (Liu 2007, PMID 17227934). Acromegaly-like features and gigantism follow chronic GH excess. Long-term safety signals exist: the French SAGhE analysis and related cohorts raised concern about excess circulatory/cerebrovascular mortality after childhood GH treatment, prompting an FDA safety review, though the larger pooled SAGhE cohort (Lancet Diabetes Endocrinol 2020) provided more reassuring overall mortality data; the question of long-term cardiovascular and neoplastic risk remains incompletely resolved. GH is contraindicated in active malignancy, acute critical illness, and proliferative diabetic retinopathy. Non-prescription "GH" products and gray-market vials carry additional risks of misidentification, contamination, and incorrect labeling that are not characterized in any controlled study.

In the two small gene-therapy trials, intramuscular AAV1.FS344 was reported as generally well tolerated over follow-up exceeding two years, but these cohorts are far too small to characterize real risk. Because follistatin broadly inhibits TGF-beta/activin signaling, theoretical and preclinical concerns include effects on reproductive tissues (follistatin was first identified as an inhibitor of FSH secretion), the pituitary-gonadal axis, vascular and cardiac remodeling, and possible influence on tumor biology, none of which are adequately resolved in humans. Gray-market "follistatin-344 peptide" products carry the additional, unquantified hazards of unverified identity, purity, sterility, and the fundamental mismatch that human data come from a delivered gene, not an injected protein. There is no established human safety profile for self-administered FS-344.

Recombinant somatropin is FDA-approved (first approved 1985–1987) for specific indications including pediatric GH deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature, idiopathic short stature, chronic renal insufficiency, adult GH deficiency, and HIV-associated wasting; non-approved uses such as anti-aging, bodybuilding, or athletic enhancement are off-label and, in the US, distribution for such uses is specifically restricted by law. GH is a prohibited substance in and out of competition under the World Anti-Doping Agency (WADA) code.

Follistatin-344 is not approved by the FDA (or any major regulator) for any indication; it has only been studied investigationally as an AAV-delivered gene therapy and is sold elsewhere strictly as a research-use-only chemical, not a medicine. Myostatin-pathway inhibition is also of interest to anti-doping bodies, and follistatin/myostatin inhibitors fall under WADA's prohibited categories.